PAM50 test is now available to classify breast cancer subtypes

December 23, 2015

Standard methods for diagnosing and treating breast cancer include anatomic staging, histological assessment, and molecular testing for ER, PR and HER2/neu protein expression. The PAM50 test is performed from formalin-fixed, paraffin-embedded tissues so that specimens are handled within routine clinical practice. "Having additional information about the tumor biology and quantitative data on biomarkers already used for treatment decisions is the first step towards personalized health care in oncology," said Bernard.

The PAM50 is the beginning of a suite of multi-analyte gene expression oncology tests offered by ARUP Laboratories and is complemented by other mutation tests (e.g., EGFR, KRAS and PIK3CA) that are already available.

"Our goal at ARUP Laboratories has always been to improve the quality and efficacy of medical care by providing accurate and actionable information derived from diagnostic laboratory tests," said Sherrie Perkins, MD, PhD, chief medical officer and director of laboratories at ARUP Laboratories. "This test represents our efforts to promote the right test for the right patient at the right time."

Source: ARUP Laboratories